Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy.
about
Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodiesThe IL-8/IL-8R Axis: A Double Agent in Tumor Immune ResistanceDistinct Functions of Neutrophil in Cancer and Its RegulationThe CXCL8-CXCR1/2 pathways in cancerThe Multifaceted Roles Neutrophils Play in the Tumor MicroenvironmentMacrophages eliminate circulating tumor cells after monoclonal antibody therapyHuman IgG3 with extended half-life does not improve Fc-gamma receptor-mediated cancer antibody therapies in micePrimary breast cancer tumours contain high amounts of IgA1 immunoglobulin: an immunohistochemical analysis of a possible carrier of the tumour-associated Tn antigen.Glycan elongation beyond the mucin associated Tn antigen protects tumor cells from immune-mediated killing.Comparison of prophylactic and therapeutic immunisation with an ErbB-2 (HER2) fusion protein and immunoglobulin V-gene repertoire analysis in a transgenic mouse model of spontaneous breast cancer.Development of IgG Mediated Antibody Dependent Cell-mediated Cytotoxicity (ADCC) in the Serum and Genital Mucosa of HIV Seroconverters.Significant Impact of Immunogen Design on the Diversity of Antibodies Generated by Carbohydrate-Based Anticancer Vaccine.Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss.The fully synthetic MAG-Tn3 therapeutic vaccine containing the tetanus toxoid-derived TT830-844 universal epitope provides anti-tumor immunity.Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18.Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastomaNatural and Induced Humoral Responses to MUC1.Effective antitumor therapy based on a novel antibody-drug conjugate targeting the Tn carbohydrate antigenThe sweet side of tumor immunotherapy.Protumor and antitumor functions of neutrophil granulocytes.Mechanisms of action of CD20 antibodies.Tn and sialyl-Tn antigens, aberrant O-glycomics as human disease markers.The Cosmc connection to the Tn antigen in cancer.Three major uncertainties in the antibody therapy of cancer.Simple sugars to complex disease--mucin-type O-glycans in cancer.Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.Trypanosoma cruzi extracts elicit protective immune response against chemically induced colon and mammary cancers.Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1.Monoclonal antibodies toward different Tn-amino acid backbones display distinct recognition patterns on human cancer cells. Implications for effective immuno-targeting of cancer.A Tn antigen binding lectin from Myrsine coriacea displays toxicity in human cancer cell lines.Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica.Antibody-dependent cell cytotoxicity in monoclonal antibody-mediated tumor immunotherapy.Insights from Fc receptor biology: a route to improved antibody reagents.The humanized anti-human AMHRII mAb 3C23K exerts an anti-tumor activity against human ovarian cancer through tumor-associated macrophages.The regulation of pre-metastatic niche formation by neutrophils.
P2860
Q21131216-0C232B3E-692C-4BA8-94BD-295D13606131Q26746986-1FA29117-5F5C-4CD0-A4C8-68C4839CC1AFQ26773228-FCF7BD1C-AB17-48B6-895E-664574A7BAF8Q28075994-4C80EA7F-17EF-42D6-9232-428A7A7BC521Q28241308-2A1B2692-8A01-455E-A02C-02F4706D5698Q30569758-403709E6-010F-42E6-B764-A8B4D48D67F4Q33707941-AC2AEFBD-0C16-4302-912B-20917865620CQ34700620-F2ECDCE5-C67D-4D35-8B7D-C88B0C0812B9Q34988382-7350E03D-A088-4D94-BA63-9A93CDEE1C3BQ35851930-A998FC86-46F9-4789-9F16-086BA2F873A2Q36479067-3BF4350F-FED4-4848-9BC2-3FA86867779FQ36497647-23ADF4E8-F937-4EE7-AF67-0E364FC50D39Q36635664-C12B8191-3B0A-47B3-820F-5CFD9A05A975Q36654041-25ADF766-5692-4386-95FE-45F4233F008CQ36797398-B288BF49-2B83-439A-AA1D-D63BAB47CC00Q37078946-4FFFB24B-70E0-4846-A586-F896101E7BEDQ37137385-18A2A787-7478-4E05-ACC4-10D308EBEC55Q37222147-916603AD-5224-474E-9EDF-60B87E058BCCQ38031282-1DD58346-50EC-44F8-8AC6-0211090B3FCAQ38046098-C96A2D8B-ADD5-45F4-BE83-9FF26A73F819Q38066195-2279C3A8-360B-40A3-B3B7-7DA434926AA5Q38121846-E0F9A99E-22DA-410E-B382-D5897BCADB88Q38197051-47057CFF-204F-4E45-AB41-5261F9255A92Q38255786-F7B0B8CC-FFA1-4604-8A2A-AA76E145B6F2Q38366325-CC21ED65-67DD-4F98-A375-0A2A8B0D49EAQ38563897-6EC6C694-5D71-4748-9F6B-3B9368A8B993Q38823310-576DE0CB-3E57-447F-9B1F-EBF698E3E2A9Q38847426-C1AD9AE6-D93C-49D7-B2FE-A546FE664905Q39162905-1CF41C0B-8848-41C3-B49A-422C41ACF5B3Q39340190-75825DDA-DAE0-4B77-B0E4-8F60EA79A9FFQ40092095-624B37A9-D467-4868-981C-224CA6788705Q41809357-44B6301B-99A1-419E-9E9A-660479300918Q43177854-3A374AA2-3F2A-492C-A0E5-9E0398F366BCQ47103062-7D798FA4-4219-4DE5-A492-71685EAC0142Q49265524-8AC87D00-3D2B-42F0-8B92-4AE039D5B15D
P2860
Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Antibody-dependent cell cytoto ...... ecific antibody immunotherapy.
@en
Antibody-dependent cell cytoto ...... ecific antibody immunotherapy.
@nl
type
label
Antibody-dependent cell cytoto ...... ecific antibody immunotherapy.
@en
Antibody-dependent cell cytoto ...... ecific antibody immunotherapy.
@nl
prefLabel
Antibody-dependent cell cytoto ...... ecific antibody immunotherapy.
@en
Antibody-dependent cell cytoto ...... ecific antibody immunotherapy.
@nl
P2093
P50
P921
P1433
P1476
Antibody-dependent cell cytoto ...... ecific antibody immunotherapy.
@en
P2093
Adèle Heitzmann
André Nicolas
Eduardo Osinaga
Otto Pritsch
Pascale Hubert
P304
P356
10.1158/0008-5472.CAN-10-4222
P407
P577
2011-06-22T00:00:00Z